NEW DELHI: After showing its worth in pharmaceutical industry, the Mankind pharma is all set to enter into the diagnostics market under its new venture- Pathkind Labs.
The Delhi based mankind pharma is reported to have invested Rs. 305 crore its new venture -Pathkind Labs. Sanjeev Vashishta, former chief executive officer of SRL Diagnostics will be the leading chief executive of Pathkind Labs reports Business Standard.
Explaining the need and importance of quality diagnostic healthcare in India specialy in rural areas, Sanjeev Vashishta former chief executive officer of SRL Diagnostics said, “We are introducing a sub-hub and spoke model as opposed to the hub and spoke model that others use.”
“There is a huge demand for quality diagnostics, especially in rural areas. Diagnostics can be used as preventive healthcare measure to reduce overall health expenditure.We want to leverage on this opportunity by providing quality services at affordable prices.”
Speaking about their initial work plan Vashishta told to ET that the company will initially start its operations from the northern region and plans to tap Uttar Pradesh, Uttarakhand and parts of Bihar in next one year. He further informed that the company will operate on a three-tier model of hub, sub-hub and multiple.
The company will have a reference lab in Gurgaon, large network labs in metros or bigger cities, and smaller rapid response labs in tier-II cities.
The company will focus more in Uttar Pradseh. Out of 11 large network labs, 8 will be opened in UP including in Lucknow, Varanasi, Meerut and Gorakhpur. Besides, Uttarakhand will have one and Bihar will have two large labs.